Efficient Brain Delivery of Neuroprotective TrkB Agonist Antibodies in Alzheimer’s Disease Using CD98hc Bispecific Shuttles
使用 CD98hc 双特异性穿梭细胞有效脑部递送神经保护性 TrkB 激动剂抗体治疗阿尔茨海默病
基本信息
- 批准号:10537474
- 负责人:
- 金额:$ 6.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAffinityAgeAgonistAlzheimer like pathologyAlzheimer&aposs DiseaseAlzheimer&aposs disease therapyAmericanAmino Acid Transport System LAnimal ModelAntibodiesAntibody AffinityAntibody DissociationsAntibody SpecificityAreaBiological ProductsBispecific AntibodiesBlood - brain barrier anatomyBrainCharacteristicsCognitive deficitsCombined Modality TherapyDataDementiaDevelopmentDiseaseEndotheliumEnzyme-Linked Immunosorbent AssayEpitopesEvaluationFluorescence-Activated Cell SortingFunctional disorderFutureGenerationsGoalsHumanImmunoglobulin GLibrariesLigandsMediatingMusNerve DegenerationNeurodegenerative DisordersNeuronsNeurotrophic Tyrosine Kinase Receptor Type 2OutcomePathway interactionsPatientsProteinsReceptor ActivationResearchSideSignal TransductionSurfaceSynapsesTFRC geneTestingTherapeuticTherapeutic antibodiesTimeTransgenic MiceVariantViralWestern BlottingWild Type MouseWorkYeastsage related neurodegenerationantagonistbrain parenchymacerebrovascularclinical efficacydesignimprovedinsightmouse modelmutantneuroprotectionnovel therapeuticspre-clinicalpreservationpreventsmall molecule therapeuticstau Proteinstherapeutic developmenttherapeutic protein
项目摘要
Alzheimer’s disease (AD) is the most common age-related neurodegenerative disease. Despite the great
potential of biologics (e.g., therapeutic antibodies) to affect AD pathophysiology, these agents are generally
unable to penetrate the blood-brain barrier (BBB), which represents their biggest hurdle to clinical efficacy. One
promising strategy is to use bispecific antibody BBB shuttles, which involve fusing IgGs to a second affinity ligand
that engages a cerebrovascular endothelial target and induces transport across the BBB. While most previous
work has focused on BBB shuttles that target transferrin receptor (TfR-1), my lab has developed a BBB shuttle
that engages CD98hc, the heavy chain of the large neutral amino acid transporter (LAT-1). Notably, our
preliminary data demonstrate superior brain parenchymal delivery and retention of IgGs shuttled via CD98hc as
compared to those shuttled via TfR-1. Importantly, this first-generation CD98hc shuttle enables brain delivery of
off-the-shelf IgGs simply by attaching a single-chain CD98hc antibody to the C-terminus of one of the two IgG
heavy chains. The objectives of this proposal are twofold: i) to define the optimal CD98hc shuttle characteristics
(CD98hc single-chain affinity, valency, and epitope) for maximal brain parenchymal delivery and retention to
guide the design of second-generation CD98hc shuttles; and ii) to generate proof-of-concept efficacy data in an
AD mouse model (tau, PS19) using a TrkB agonist antibody that induces neuroprotective signaling. For the first
objective, I hypothesize that BBB shuttles with monovalent CD98hc single-chain antibodies (as used in the first-
generation shuttle) and reduced CD98hc single-chain antibody affinity (relative to the first-generation shuttle) will
maximize antibody concentrations in the brain parenchyma by improving antibody dissociation at the abluminal
side of the brain endothelium, as observed for TfR-1 shuttles. For the second objective, I hypothesize that
CD98hc shuttles that deliver TrkB agonist IgGs to the brain parenchyma of tau transgenic mice will reduce
neuronal and synaptic loss and cognitive deficits. This hypothesis is supported by the partial efficacy of non-
shuttled TrkB antibodies delivered systemically and high efficacy of viral brain delivery of the TrkB ligand in AD
mouse models. Therefore, I propose in Aim 1 to develop an optimized second-generation CD98hc shuttle by
evaluating the impact of CD98hc single-chain antibody affinity, valency, and epitope on antibody concentrations
in the mouse brain parenchyma as a function of time. Next, in Aim 2, I propose to evaluate the ability of a first-
generation CD98hc shuttle to deliver a TrkB agonist IgG to the brain parenchyma, to activate TrkB in wild-type
and tau (PS19) transgenic mice, and to mediate neuroprotection in tau transgenic mice. A key expected outcome
is the development of an optimized CD98hc shuttle that can be used to deliver a wide range of existing
therapeutic antibodies to the brain parenchyma. A second key expected outcome is preclinical data for TrkB
agonism in AD mouse models. These findings are expected to enable future studies of single and combination
therapies using antagonist and agonist antibodies that target mechanistically unique pathways.
阿尔茨海默病(AD)是最常见的与年龄相关的神经退行性疾病。尽管有很大的
生物制品(例如,治疗性抗体)影响AD病理生理学的可能性,这些制剂通常是
无法穿透血脑屏障(BBB),这是他们临床疗效的最大障碍。一
有希望的策略是使用双特异性抗体bbb穿梭,这涉及到将免疫球蛋白与第二个亲和配体融合。
这与脑血管内皮细胞靶点结合,并诱导跨血脑屏障的运输。虽然之前的大多数
工作重点是针对转铁蛋白受体(TFR-1)的血脑屏障穿梭,我的实验室已经开发出一种血脑屏障穿梭
这与CD98hc结合,CD98hc是大的中性氨基酸转运体(LAT-1)的重链。值得注意的是,我们的
初步数据显示通过CD98hc AS运送的IGG具有较高的脑实质递送和滞留能力
与通过TFR-1穿梭的那些相比。重要的是,这一第一代CD98hc航天飞机使大脑能够传递
通过将单链CD98hc抗体连接到两种免疫球蛋白之一的C末端,即可获得现成的免疫球蛋白
沉重的锁链。这项建议的目标有两个:i)确定CD98hc的最佳穿梭特性
(CD98hc单链亲和力、价位和表位),最大限度地将脑实质传递和保留到
指导第二代CD98hc航天飞机的设计;以及ii)在
使用TrkB激动剂抗体诱导神经保护信号的AD小鼠模型(tau,PS19)。对于第一次
目的:我假设血脑屏障携带单价CD98hc单链抗体(如第一次使用的那样-
和降低的CD98hc单链抗体亲和力(相对于第一代航天飞机)将
通过改善抗体在脑实质中的解离,最大限度地提高脑实质中的抗体浓度
大脑内皮细胞的一侧,如TFR-1航天飞机所观察到的。对于第二个目标,我假设
将TrkB激动剂IgGS运送到tau转基因小鼠脑实质的CD98hc航天飞机将减少
神经元和突触丢失以及认知缺陷。这一假说得到了非药物的部分疗效的支持
穿梭TrkB抗体全身性高效携带TrkB配体病毒脑内注射治疗AD
老鼠模型。因此,我在目标1中建议通过以下方式开发优化的第二代CD98hc航天飞机
评估CD98hc单链抗体亲和力、效价和表位对抗体浓度的影响
在小鼠脑实质中作为时间的函数。接下来,在目标2中,我建议评估第一个-
一代CD98hc穿梭运送TrkB激动剂Ig G到脑实质,激活野生型TrkB
和tau(PS19)转基因小鼠,并在tau转基因小鼠中介导神经保护。一个关键的预期结果
是否正在开发一种优化的CD98hc航天飞机,可以用来交付各种现有的
脑实质的治疗性抗体。第二个关键的预期结果是TrkB的临床前数据
阿尔茨海默病小鼠模型中的激动症。这些发现有望使未来对单一和组合的研究成为可能
使用拮抗剂和激动剂抗体靶向机械上独特的通路的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael John Lucas其他文献
Michael John Lucas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael John Lucas', 18)}}的其他基金
Efficient Brain Delivery of Neuroprotective TrkB Agonist Antibodies in Alzheimer’s Disease Using CD98hc Bispecific Shuttles
使用 CD98hc 双特异性穿梭细胞有效脑部递送神经保护性 TrkB 激动剂抗体治疗阿尔茨海默病
- 批准号:
10786022 - 财政年份:2022
- 资助金额:
$ 6.72万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 6.72万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 6.72万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 6.72万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 6.72万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 6.72万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 6.72万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 6.72万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 6.72万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 6.72万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 6.72万 - 项目类别:
Continuing Grant